How does risdiplam actually protect my motor neurons and stop muscle weakness?
Risdiplam tells your body to make more SMN protein by fixing how your SMN2 gene is read. In clinical trials, 50–60% of infants with type 1 SMA achieved major motor milestones like sitting and standing, compared to 0% in the placebo group [3].
Your body has two SMN genes: SMN1 (broken in SMA) and SMN2 (works but makes incomplete protein). Risdiplam is a small molecule that changes how SMN2 is processed, so it makes full-length, working SMN protein instead of a shortened, useless version. In the FIREFISH trial (type 1 SMA), 60% of infants on risdiplam sat independently by month 12, versus 0% in placebo [3].
SMN protein is like a factory worker that keeps motor neurons (the nerve cells controlling your muscles) alive and healthy. When you don't have enough SMN, these neurons slowly die, and your muscles get weaker. Risdiplam floods your motor neurons with SMN, so they stay strong and keep sending signals to your muscles [5].
You take risdiplam by mouth once a day as a 5 mg tablet or 0.75 mg/mL powder mixed in liquid. It reaches your brain and spinal cord through your bloodstream and starts working within days. Most patients see improvement or slowing of weakness within 3–6 months, though some take longer [2].
Ask your neurologist: 'Will risdiplam work better if I start it earlier, before I have symptoms?' Early treatment in presymptomatic carriers prevented all motor symptoms at 24 months [2].